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ABSTRACT 
Background: The proposed involvement of CD151 in breast cancer (BCa) progression is 
based on findings from studies in invasive ductal carcinoma (IDC). IDC and invasive lobular 
carcinoma (ILC) represent distinct disease entities. Here we evaluated clinical significance of 
CD151 alone and in association with integrin α3β1 in patients with ILC in context of the data 
of our recent IDC study. 
Methods: Expression of CD151 and/or integrin α3β1 was evaluated in ILC samples 
(No=117) using immunohistochemistry. The findings were analysed in relation to our results 
from an IDC cohort (No=182) demonstrating a prognostic value of an expression of 
CD151/integrin α3β1 complex in patients with HER2-negative tumours. 
Results: Unlike in the IDCs, neither CD151 nor CD151/α3β1 complex showed any 
correlation with any of the ILC characteristics. Lack of both CD151 and α3β1 was 
significantly correlated with poor survival (p = 0.034) in lymph node negative ILC N(-) cases. 
CD151
−/α3β1− patients had 3.12-fold higher risk of death from BCa in comparison to the rest 
of the ILC N(-) patients.  
Conclusions: Biological role of CD151/α3β1 varies between ILC and IDC. CD151/α3β1 
assessment might help to identify ILC N(-) patients with increased risk of distant metastases.  
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INTRODUCTION 
The tetraspanin protein CD151 (Tspan24) has recently emerged as a new candidate indicator 
of tumour cell invasiveness (Boucheix and Rubinstein, 2001; Hemler, 2005; Zoller, 2009). 
Elevated expression of CD151 protein and its involvement in tumour progression have been 
observed in various human malignancies (Romanska and Berditchevski, 2011). In breast 
cancer (BCa), in particular, high expression of tetraspanin CD151 was shown to correlate with 
axillary lymph node involvement and patient poor overall survival (Kwon et al., 2012; 
Novitskaya et al., 2014; Sadej et al., 2009). The role of CD151 in tumour invasive and 
metastatic progression is thought to be relying on its ability to form complexes with laminin-
binding integrin receptors (i.e. α6β1, α3β1, α6β4) (Sadej et al., 2014) and its involvement in 
the regulation of cell-cell and cell-matrix interactions (Johnson et al., 2009). The underlying 
signalling pathways are likely to depend on adhesion-dependent and co-ordinated activation 
of small Rho and Ras GTPases, c-Akt and p38 (Novitskaya et al., 2014). It was also proposed 
that the CD151/α3β1 complex is directly linked to cadherin and catenin, thus regulating E-
cadherin mediated cell-cell adhesion (Chattopadhyay et al., 2003). A suppressive role of the 
CD151/α3β1 complex, recently demonstrated in ovarian cancer, has been linked to 
stabilization of integrin α3β1− and E-cadherin-mediated cell-cell contacts (Baldwin et al., 
2014). In addition to its role in regulation adhesion-dependent outside-in signalling pathways, 
CD151 might contribute to mammary tumourigenesis via ErbB2/HER2 (Deng et al., 2012; 
Novitskaya et al., 2014). Interestingly, clinical analyses of breast cancer patients showed that 
the elevated expression of CD151 correlated with poor overall survival only of patients with 
HER2-negative (luminal A and quintuple-negative) tumours (Kwon et al., 2012). Moreover, 
an impact of CD151/α3β1 on IDC patients survival was shown to be inversely correlated with 
the level of HER2 expression (Novitskaya et al., 2014).  
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Existing knowledge of CD151 involvement in mammary tumourigenesis is almost exclusively 
based on clinical and in vitro studies of the invasive ductal carcinoma (IDC). However, it is 
becoming increasingly apparent that CD151 might have diverse, even opposing roles, in 
different biological contexts and its clinical significance should be investigated in relation to 
the phenotypical and histological variants of the tumour (Voss et al., 2011).  
 
Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of newly 
diagnosed breast carcinomas. Classical ILCs are characterized by an outgrowth of small, 
uniform discohesive neoplastic cells that invade the stroma in a single-file pattern (Sikora et 
al., 2014). The majority of ILC tumours are of low histological grade and preferentially 
display a luminal A phenotype (ER+/PR+/HER2-) (Weigelt et al., 2010). Classical ILCs lack 
E-cadherin expression, which is considered a defining feature of this BCa type (Sikora et al., 
2014). Recent studies demonstrated that ILCs differ from grade- and molecular subtype-
matched IDCs in the transcriptomic profiles related to cell adhesion, cell-cell signalling and 
metastatic pattern indicating that IDCs and ILCs represent distinct disease entities (Sikora et 
al., 2014; Weigelt et al., 2010). 
 
Due to the relatively low incidence of ILC as well as the paucity of available research models 
(Sikora et al., 2014), the mechanisms underlying its pathophysiology are poorly understood. It 
is likely that the role of CD151 in progression of E-cadherin-inactivated ILCs, and hence its 
impact on patients outcome differs from those documented in the more common IDCs. To 
date CD151 expression has been studied only in a few ILC cases, a small part (2.9%; 25/886) 
of a large cohort analysed according to the phenotypical, not the histological subtypes (Kwon 
et al., 2012). More information is available regarding expression of integrins in ILC. Most 
reports are in agreement that malignant ILC phenotype is associated with decrease of 
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expression of a range of integrin subunits. However, independently, the integrins seem to be 
of limited clinical value as no correlation between their expression, histological grade, nodal 
involvement, proliferative activity or, above all, the overall survival has ever been found 
(Gonzalez-Angulo et al., 2006; Gui et al., 1995; Lanzafame et al., 1996; Gonzalez et al., 
1999).   
 
The Į3ȕ1 integrin forms a stoichiometric complex with the tetraspanin CD151, and the 
interaction with CD151 is functionally important in Į3 integrindependent matrix remodeling 
and cell spreading (Kazarov et al., 2002). The aim of our study was to assess clinical 
significance of CD151 alone and in association with integrin α3β1 in a group of patients with 
ILC. The findings were analysed in context of our recent IDC study demonstrating a 
prognostic value of an expression of integrin CD151/α3β1 complex in patients with HER2-
negative tumours (Novitskaya et al., 2014). 
 
MATERIAL AND METHODS 
Patient Selection and Samples  
The study included radical surgery specimens of primary ILC from 117 patients treated 
between 2000 and 2008 at three sites: 1) the Oncology Department of Copernicus Memorial 
Hospital in àódĨ, Poland, 2) the UHB NHSFT, Birmingham, UK and 3) the Leeds Teaching 
Hospitals NHS Trust, Leeds, UK. All samples were obtained according to the local ethical 
regulations (project ethics licence: # RNN/174/11/KE). The characteristics of the study 
population are summarized in Table 1. Follow-up period was defined as the time from surgery 
to the last observation for censored cases or death for complete observations. 
 
Immunohistochemistry  
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Serial 5 µm paraffin sections of formalin-fixed blocks were processed for 
immunohistochemistry for CD151 (mouse anti-human; 1:100; Novocastra, UK) and α3β1 
(INTA3) (goat anti-human; 1:200, Santa Cruz, UK) using protocols described previously 
(Novitskaya et al., 2014). Immunostaining for E-cadherin (mouse anti-human, 1:50; 
Novocastra, UK) was used to confirm the initial pathological diagnosis of ILC (E-cadherin-
positive samples were excluded from the study). As a negative
 
control for the 
immunostaining, primary antibodies were replaced by non-immune sera.  
 
Scoring of immunostaining for CD151 was based on Hofmanns method for membranous 
reactivity of ErbB2 (Hofmann et al., 2008) and modified as follows: i) 0/negative  no 
reactivity or only partially membranous reactivity in  10% of tumour cells; ii) 1+/negative  
faint membranous or partially membranous in  10% of tumour cells; iii) 2+/positive  weak 
to moderate complete membranous in  10% of tumour cells; iv) 3+/positive  strong 
complete membranous in  10% of the tumour cells. Immunoreactivity for α3β1 was scored 
as follows: i) 0/negative  no reactivity, ii) 1+/positive  faint membranous and/ or 
cytoplasmic staining in  10% of tumour cells; iii) 2+/positive  weak to moderate 
membranous and/or cytoplasmic staining in  10% of tumour cells; iv) 3+/positive  strong 
membranous and/or cytoplasmic staining in  10% of the tumour cells. Immunohistochemical 
staining was evaluated and scored independently by two observers (HMR and RK* or HMR 
and SC). The agreement on staining intensity was > 90%. Where there was disagreement, 
intensity was determined by consensus. Dichotomization of the final scores into: a)negative 
and b)positive for CD151/ 0-2; INTA3/ 0 and CD151/3 and INTA3/1-3, respectively, was 
guided by intensity of immunostaining in positive controls recommended by the 
manufacturer. 
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Statistical analysis 
Overall survival was calculated from the date of surgery to the date of death or the last follow-
up, as recommended by the Kaplan-Meier method. Differences in survival distributions were 
compared using log-rank test. Data for patients who died from other causes than breast cancer 
were censored at the time of death. Univariate analysis of overall survival was performed 
using the Cox proportional hazards regression model. Parameters showing a significant 
correlation (p< 0.05) were included in the multivariate logistic regression analysis. Pearsons 
Ȥ2 test or Fishers exact test were used to assess the associations between expression of 
CD151 and α3β1 alone and their co-expression and clinicopathological variables. The results 
were considered statistically significant when two-sided p was less than 0.05. The analyses 
were performed using the Statistica 9.1 and and Statistica 10 (StatSoft Inc. Tulsa, OK, USA) 
software.   
Data on cancer recurrence were available in only four cases which precluded the DFS 
analysis. 
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RESULTS 
 
An impact of CD151/ on tumour biology differs between ILC and IDC. 
In normal gland, both CD151 and α3β1 showed moderate to strong, predominantly, 
membranous immunoreactivity, confined to the basal and lateral surfaces of the myoepithelial 
cells, with no or very weak staining in luminal epithelial cells (Fig. 1A). Similarly, in ILCs, 
CD151 and α3β1 were localized mainly to the membrane of tumour cells and there was a 
significant correlation (p = 0.012) between levels of their expression (Table 2A). We 
observed four distinct patterns of immunoreactivity for CD151/α3β1: 1) CD151+/α3β1+ in 
55/117 (49.01%); 2) CD151-/α3β1- in 20/117 (17.09%); 3) CD151+/α3β1- in 28/117 
(23.94%) and 4) CD151-/α3β1+ in 14/117 (11.96%) cases (Fig. 1B-E). Interestingly, the level 
of CD151 expression (but not expression of α3β1) on cancer cells was similar to that 
observed on endothelial cells of intratumoural vessels (Fig. 2). 
There was no significant correlation between the level of α3β1 expression and any of tumour 
characteristics (Table 2A). On the other hand, expression of CD151 assessed alone was 
inversely associated with tumour size (p = 0.047) and stage (p = 0.019), thus indicating that 
CD151 might have an ability to suppress proliferation of cells and progression of disease. 
Interestingly, positivity for both CD151 and α3β1 (CD151+/α3β1+) was significantly 
associated only with grade (p = 0.019). These results suggest that phenotypic dedifferentiation 
and adopting of anaplastic features by epithelial cells in ILC are associated with CD151 
acting in a complex with α3β1.   
 
We have previously reported that in IDC, in contrast to ILC, CD151 expression showed a 
positive association with stage (p = 0.030) and inverse with tumour grade (p = 0.041). We 
have also demonstrated that, when assessed in combination, positivity for CD151 and/or α3β1 
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correlated closer than CD151 alone with stage of disease (p<0.001 vs. p = 0.03 for 
CD151/α3β1 vs. CD151, respectively) (Novitskaya et al., 2014). Here we have expanded our 
previous analyses and evaluated co-expression of CD151 and α3β1 in the context of 
histopathological and clinical characteristics of the IDC cohort. The results showed, that in 
contrast to ILCs, combined positivity for both CD151 and α3β1 showed no correlation with 
any of the clinicopathological features in IDCs (Table 2B). Taken together, these results 
suggest that the involvement of CD151 and its principal transmembrane partner, the integrin 
α3β1, in tumour development and progression is likely to differ between histological 
subtypes of breast cancer.   
 
In ILC, in contrast to IDC, neither CD151 nor  hold prognostic value. 
Neither CD151 nor α3β1 analysed alone were of any prognostic value in ILCs (Table 3A). In 
contrast, in IDC, as shown previously, CD151-positive patients had 1.88-fold higher risk of 
death from breast cancer in comparison with CD151-negative patients. Moreover, a 
multivariate statistical analysis identified CD151 as an independent marker (p = 0.0172) of 
poor prognosis in IDC (Table 4). In neither ILC nor IDC co-expression was significantly 
associated with patient survival. Furthermore, while in the IDC cohort, clinicopathological 
characteristics commonly recognized as independent prognostic factors (tumour size, lymph 
node status, stage), were significantly associated with poor survival, none of them held any 
prognostic value in our ILC study population (Table 3A/B).  
 
Lack of CD151/  expression is associated with poor survival in node–negative ILC. 
As CD151, acting in partnership with α3β1, is thought to affect invasive spread of tumour 
cells, we analysed prognostic values of CD151 and/or α3β1 in the ILC cohort in relation to 
the lymph node status. Results presented in Table 5 demonstrate that neither CD151 nor α3β1 
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assessed alone or in combination had any significant prognostic value in any of the subgroups. 
Only a trend towards statistical significance (p=0.082) was seen for CD151 in nodenegative 
patients [ILCN(-)]. Furthermore, in the ILCN(-) subgroup, the data were suggestive that the 
presence of either CD151 or α3β1 could be favourable to the prognosis but their co-
expression had no additive effect on patient survival. Thus, we looked next at the 
relationships between CD151 and/or α3β1  and  tumour characteristics in the lymph node-
negative subgroup (characteristics of the group are summarized in Table 6A). Table 6B 
demonstrates that, as in the whole group, significant correlations between: 1) expression of 
CD151 and α3β1 (p = 0.018); 2) CD151 and tumour size (p = 0.035) and 3) CD151/α3β1 and 
grade (p = 0.029) were maintained. Univariate analysis in ILC N(-) cases showed that lack of 
combined expression of CD151 and α3β1 was significantly correlated with poor patient 
survival (p = 0.034)  and was the only prognostic factor in this group (Table 6C). 
CD151/α3β1− negative patients had 3.12-fold higher risk of death from breast cancer in 
comparison to the rest of the patients with no lymph node involvement and five-year 
estimated survival rates were 64% vs 91%, respectively (Fig. 3). 
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DISCUSSION 
An overexpression of CD151/Tspan24 has been repeatedly reported as a negative predictor of 
overall survival of patients with invasive ductal breast carcinoma (IDC) (Sadej et al., 2009; 
Yang et al., 2008; Kwon et al., 2012; Novitskaya et al., 2014) but nothing is known about its 
clinical significance in invasive lobular breast cancer (ILC). Here we demonstrate that, in 
contrast to IDC, loss of CD151 expression in complex with that of its principal molecular 
partner, the integrin α3β1, is significantly associated with poor survival in patients with 
lymph node-negative ILC. There have been a few attempts to establish an expression 
signature of a risk of distant metastasis in primary lymph-nodenegative IDC (Tutt et al., 
2008; Wang et al., 2007; Mirza et al., 2002). To the best of our knowledge, this is the first 
study providing information on prognostic factors in a subgroup of lymph-nodenegative ILC 
patients.  
 
Results of our study provide support for the notion of biological diversity of CD151 in human 
cancer. Acting alone and/or in complex with laminin-binding integrins, CD151 has been 
linked with various aspects of carcinogenesis (Palmer et al., 2014; Sadej et al., 2014). Whilst 
its pro-migratory and pro-invasive functions are well established, it was also reported that in 
certain cell types the presence of CD151 is associated with suppression of motility. For 
example, its downregulation induced by hypoxic stress at the primary site in colon cancer was 
shown to decrease adhesion of cells to the extracellular matrix and enhanced cell motility 
(Chien et al., 2008). Similarly, both up- and down-regulation of integrin α3β1 expression 
have been correlated with tumour invasion and poor prognosis
 
(Adachi et al., 1998; 
Fukushima et al., 1998; Gustafson et al., 2013). Furthermore, the CD151/α3β1 complex has 
been recently shown to suppress ovarian tumour growth (Baldwin et al., 2014). Although in 
our study no prognostic value could be ascribed to either CD151 or α3β1 assessed alone, their 
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independent suppressor-like functions cannot be excluded. Further mechanistic investigation 
would be required to evaluate an actual impact of a loss of the CD151/α3β1 complex on ILC 
tumour bevaviour.  
 
Increasing evidence suggests that ILCs and IDCs are biologically different. This is reflected 
in disparities in morphological and phenotypic characteristics, transcriptomic profiles related 
particularly to cell-cell and cell-matrix interactions (Weigelt et al., 2010), as well as 
responsiveness to neoadjuvant therapy (Korkola et al., 2003). As demonstrated by several 
genomic studies, the only consistent finding characterizing ILC tumours is inactivation of 
CDH1 (E-cadherin, cadherin-1) (Sikora et al., 2013; Weigelt et al., 2010; Weigelt et al., 2008; 
Bertucci et al., 2008) and indeed, lack of E-cadherin expression is considered a hallmark of 
ILC. Although the role of E-cadherin in tumour onset and progression is still largely 
unknown, its inactivation alone is clearly not sufficient to induce neoplastic growth. It has 
been shown that combined loss of E-cadherin and p53, but not E-cadherin alone, in murine 
mammary epithelial cells induces metastatic carcinomas that resemble human ILC (Derksen 
et al., 2006).  
 
There are several reports suggesting that an association of CD151 with integrin Į3ȕ1 might be 
important for regulation of E-cadherin-dependent cell-cell interactions. In mouse kidney, the 
CD151/integrin Į3ȕ1, acting as both an organizer and a component of a large multimolecular 
complex containing E-cadherinȕ-catenin, promoted its association with the actin 
cytoskeleton and cadherin-mediated cellcell adhesion. Deletion of integrin α3ȕ1 in this 
system was found to disturb E-cadherin localization and function (Chattopadhyay et al., 
2003). In highly expressing E-cadherin human keratinocytes (HaCat cell line), blocking of 
CD151 supported cell dispersal (Chometon et al., 2006), while CD151 overexpression 
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enhanced carcinoma cell-cell association (Shigeta et al., 2003). Similarly, in A431 epithelial 
carcinoma cells, near total silencing of CD151 destabilized E-cadherin-dependent cell-cell 
junctions . However, it was not the disruption 0f the E-cadherin regulatory complex but an 
excessive RhoA activation and disorganization of actin fibres at the cell-cell junctions, 
induced by loss of CD151, that led to the enhancement of cell migration (Johnson et al., 
2009). Through stabilization of E-cadherin based cell-cell interactions, CD151 was suggested 
to counteract the metastatic progression of endometrial cancer (Voss et al., 2011). Activation 
of Rho/ROCK signalling axis triggered by loss of E-cadherin was recently demonstrated to be 
responsible for induction of anoikis resistance and invasive phenotype in a mouse model of 
human ILC (Schackmann et al., 2011). Interestingly, results of our own study have shown 
that in IDC cells, depletion of CD151 and Į3ȕ1 caused increase of active RhoA (Novitskaya 
et al., 2014). Taken together, these findings seem to suggest that although loss of E-cadherin 
is a pre-requisite of the lobular phenotype, other factors, including, perhaps, the CD151-Į3ȕ1 
partnership, also contribute to invasive behaviour of cancer cells.  
 
Results of our study demonstrated that unlike IDC, lack of both CD151 and integrin Į3ȕ1 
correlated with decreased survival of patients with lymph-node-negative ILCs. Unlike IDC, 
ILC tumour cells are deprived of E-cadherin expression and the function and significance of 
the CD151/Į3ȕ1 complex in biology of E-cadherinnegative cells are poorly characterized. 
However, it is conceivable that in this particular biological context, as in the settings 
described above, the CD151/Į3ȕ1 complex is controlling cell-cell adhesion and loss of E-
cadherin contributes but is not decisive in destabilization of cell-cell contacts and 
enhancement of cell migration.  
 
14 
 
The pathogenesis of IDC and ILC seems indeed to be governed by distinct mechanisms. Not 
only the high expression of CD151, but also the lymphnode status, one of the most clinically 
important indicators of poor prognosis in IDC, was not correlated with survival of patients in 
our ILC study population. Instead, our results showed that the combined absence of CD151 
and α3β1 was a negative prognostic factor in patients with no lymph node involvement. This 
unexpected finding gives a new insight into the biology of ILC and possible contribution of 
CD151 and α3β1 to disease progression. CD151 is highly expressed in endothelial cells and 
is thought to regulate pathologic angiogenesis. It has also been demonstrated that CD151 
plays an important role in maintaining integrity of endothelial layer (Zhang et al., 2011). Our 
immunohistochemical analysis showed that the level of CD151 expression on endothelial 
cells was correlated with that seen on tumour-associated endothelium. While the mechanisms 
underlying this phenotypic unity remains unknown, it is possible that the compromised 
integrity of CD151-negative endothelium would facilitate intravasation of CD151-negative 
cells. Whatever the underlying mechanisms, results of our study indicate that loss of CD151-
α3β1 may serve as a potential prognostic marker of poor survival in a subgroup of patients 
deemed to carry a low risk of cancer-related death (i.e. lymph-node negative). This could have 
important clinical implications by helping to identify patients likely to benefit from adjuvant 
therapy. 
 
In summary, results of our comparative analysis of clinical significance of CD151/integrin 
α3β1 in ILC and IDC highlight considerable differences in biology between these two BCa 
types. Furthermore, the study suggests that evaluation of the level of CD151/α3β1 expression 
might provide important information on behaviour of ILC tumours and identify patients with 
increased risk of distant metastases, commonly considered ineligible for routine adjuvant 
therapy.  
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TITLES AND LEGENDS TO FIGURES 
 
Figure 1. Expression of CD151 and in: 
A. Normal gland (x100; insets x400). Both CD151 and α3β1 show moderate to strong, 
predominantly, membranous immunoreactivity, confined to the basal and lateral 
surfaces of the myoepithelial cells, with no or very weak staining in luminal epithelial 
cells. 
B. ILC  cells of similar areas of the tumour display various levels of CD151/α3β1 
immunoreactivity representing four predominant phenotypes: B) CD151+/α3β1+ 
(55/117; 49.01%); C) CD151+/α3β1- (28/117; 23.94%) D) CD151-/α3β1- (20/117; 
17.09%), and E) CD151-/α3β1 + (14/117; 11.96%)  
 
Figure 2. Expression of CD151 in intratumoural vessels (x400). Level of expression in 
endothelial cells of intratumoural vessels (asterisks) is consistent with that in epithelial 
cells of adjacent tumour (arrows) (A - high; B - moderate; C - negative ).  
 
Figure 3. Kaplan-Meier curves of overall survival for patients with invasive lobular 
breast cancer. 
Overall survival of patients with tumours negative for both CD151and α3β1 (1) in 
relation to the rest of the cohort (0).  
 
 
 



  
Table 1. Patient characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
In the ILC group data available for: 
1) 107 patients 
2) 
116 patients 
3) 115 patients 
4)108 patients 
5) 113 patients 
6) 106 patients 
 
Feature ILC IDC 
Number of patients 117 182 
Age (years) 
     < 50 
      50 
 
21 
96 
 
56 
127 
Disease stage 1) 
    I 
    II 
    III 
 
34 
60 
13 
 
44 
93 
45 
 
T status 2) 
    T1 
    T2 
    T3 
    T4 
 
52 
48 
15 
1 
 
61 
112 
1 
8 
Grade 3) 
    1 
    2-3 
 
21 
94 
 
105 
77 
Nodal status 4) 
   Negative 
   Positive 
 
64 
44 
 
92 
90 
Steroid receptor status 5) 
   Negative 
   Positive 
 
 
11 
102 
 
79 
103 
HER2 status 6) 
  Negative 
   Positive 
 
 
102 
4 
 
 
151 
31 
  
Table 2.  
Association between CD151 and/α3β1 expression and clinicopathological features. 
A.   
Feature P value 
ILC 
α3β1  
(high: n=69)
CD151  
(high: n=83) 
CD151 /α3β1 
(high: n=55) 
α 3  0.012  
CD151 0.012   
Size 0.574 0.047 0.381 
Nodes 0.464 0.277 0.101 
Stage 0.656 0.019 0.387 
Grade 0.093 0.343 0.019 
ErbB2 0.092 0.881 0.249 
ER/PR  0.694 0.471 0.425 
 
B. 
 
 
           
 
 
 
 
 
 
 
Feature P value 
IDC 
α3β1  
(high: n=32) 
CD151  
(high: n=87) 
CD151 /α3β1 
(high: n=26) 
α 3β1  <0.001  
CD151 <0.001   
Size 0.599 0.497 0.499 
Nodes 0.271 0.076 0.413 
Stage 0.545 0.030 0.174 
Grade 0.163 0.041 0.162 
ErbB2 >0.999 0.015 0.995 
ER/PR  0.663 0.819 0.797 
  
 
Table 3.  Univariate analysis of prognostic factors. 
A. 
Factor 
ILC 
HR 95%CI P value 
α 3β1 0.80 0.39-1.61 0.750 
CD151  0.56 0.28-1.14 0.109 
CD151/ α 3β1 0.72 0.35-1.49 0.380 
(T1 vs T2-4) 1.78 0.84-3.78 0.165 
Nodal status 1.61 0.78-3.31 0.195 
Stage (I vs II vs III) 2.08 0.85-5.11 0.111 
ER/PR 0.46 0.17-1.19 0.110 
HER2 NA
#
 NA
#
 NA
#
 
Grade (G1-2 vs G3) 1.46 0.55-3.87 0.441 
B. 
Factor 
IDC 
HR 95%CI P value 
α 3β1 1.10 0.60-2.03  0.750 
CD151  1.88 1.15-3.08  0.012 
CD151/ α 3β1 0.98 0.48-1.98  0.952 
(T1 vs T2-4) 1.77 1.30-2.40       <0.001 
Nodal status 3.01 1.78-5.10       <0.001 
Stage (I vs II vs III) 1.81 1.27-2.57       <0.001 
ER/PR 0.53 0.33-0.87   0.011 
HER2 2.07 1.18-3.64   0.012 
Grade (G1-2 vs G3) 1.24 0.76-2.01   0.383 
 
NA – not analyzed 
#
 only 4 HER2 – positive 
 
  
 
Table 4.  Multivariate analysis of prognostic factors.  
Factor 
IDC 
HR 95%CI P value 
CD151  1.92 1.12-3.31 0.0172 
(T1 vs T2-4) 1.98 0.94-4.15 0.0711 
Nodal status 4.11 2.04-8.29 <0.0001 
Stage (I vs II vs III) 0.68 0.38-1.23 0.2063 
ER/PR 0.53 0.32-0.91 0.0198 
HER2 1.20 0.71-2.04 0.1927 
 
  
Table 5.  Univariate analysis of prognostic value of CD151 and/or  in relation to 
lymph node-status.  
 
 
Factor 
ILC N(+) ILC N(-) 
HR 95%CI P value HR 95%CI P 
value
α 3β1 1.28 0.45-3.60 0.641 0.46 0.16-1.31 0.146
CD151  0.64 0.22-1.87 0.412 0.40 0.14-1.22 0.082
CD151/ α 3β1 1.02 0.35-3.00 0.970 0.72 0.35-1.49 0.187
 
  
Table 6. Lymph node – negative subgroup.  
 
A. Patients characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data available for: 
1) 63 patients 
2) 62 patients 
3) 63patients 
 
 
 
 
Feature ILC 
Number of patients 64 
Age (years) 
     < 50 
      50 
 
10 
54 
Disease stage 1) 
    I 
    II 
    III 
 
34 
28 
1 
T status 1) 
    T1 
    T2-T4 
      
 
34 
29 
Grade 2) 
    1 
    2-3 
 
13 
49 
Steroid receptor status 3) 
   Negative 
   Positive 
 
 
5 
58 
HER2 status 
  Negative 
    
 
64 
 
 2 
 
B. Association of CD151 and/or α3  and tumour characteristics. 
 α3  (high: n=38) CD151  
(high: n=47) 
CD151 /α3  
(high: n=32) 
α 3β1  0.018  
CD151 0.018   
Tumour size (T1 vs T2-4) 0.312 0.035 0.892 
Grade 0.079 0.342 0.029 
HER2 NA
*
 NA
*
 NA
*
 
ER  0.377 0.999 0.192 
PR NA
#
 NA
#
 NA
#
 
 
*  - all tumors were HER2- 
# - lack of data for 45 cases 
 
C. Univariate analysis of prognostic factors 
Factor 
ILC N(-) 
HR 95%CI P value 
α 3β1 0.462 0.16-1.31 0.146 
CD151  0.402 0.14-1.22 0.082 
CD151/ α 3β1 0.724 0.35-1.49 0.187 
CD151-/α 3β1- 3.125 1.09-8.99 0.034 
Tumour size (T1 vs T2-4) 1.780 0.61-5.18 0.290 
Grade 1.361 0.36-5.14 0.650 
ER 0.372 0.08-1.72 0.206 
 
 
